In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deals in Depth: February 2010

Executive Summary

Overall alliance money was low in comparison to January, with no deals rising over the $150mm potential deal value mark. Standing out were GSK's microRNA collaboration with Regulus that could be worth up to $150mm. M&A activity was led, by far, by Merck KGAA's $7.2bn takeover of life sciences company Millipore. Biopharma financing dollars fell in comparison to January numbers, while device financing totals came in higher.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts